In a major scientific advancement, researchers at Duke University have developed a groundbreaking enzyme that significantly expands the capabilities of CRISPR gene editing technology. This breakthrough allows for precise targeting of almost any human gene, opening up new possibilities for treating a wide range of diseases.

The original CRISPR system could only target a limited portion of the human genome, limiting its potential applications. However, the new method developed by the Duke University engineers overcomes this limitation, providing access to nearly every gene in the human genome. This advancement has the potential to revolutionize the field of gene therapy and genome engineering.

Collaborating with renowned institutions such as Harvard University, Massachusetts Institute of Technology, University of Massachusetts Medical School, University of Zurich, and McMaster University, the Duke University team published their findings in the prestigious journal Nature Communications.

By utilizing the CRISPR-Cas system, which is an immune system present in bacteria, the researchers were able to employ RNA molecules and CRISPR-associated (Cas) proteins to accurately target and destroy the DNA of specific genes. This precision allows for the modification of previously inaccessible genetic mutations associated with diseases such as Rett syndrome and Huntington's disease.

The new enzyme, named SpRYc, combines the strengths of two separate variants, offering improved accuracy and a broader range of DNA editing possibilities. While further research is needed to explore its full potential, the development of this enzyme marks a significant step forward in the field of gene editing.

With the ability to target almost any human gene with precision, scientists are now poised to unlock new treatment options and potentially find cures for previously untreatable genetic disorders. The future of precision medicine looks brighter than ever with the advent of this groundbreaking enzyme.